Kubo Y, Okuda K, Hashimoto M, Nagasaki Y, Ebata H
Gastroenterology. 1977 Jun;72(6):1217-20.
Hepatitis B surface antigen (HBsAg), anti-HBs, and anti-HB core (HBc) were measured in 124 patients with hepatocellular carcinoma (HCC) in comparison with 299 control subjects of comparable ages, and in 48 cases of chronic hepatitis and 52 cases of hepatic cirrhosis. It was found that 72.6% of the HCC patients were positive for anti-HBc, and 80.6% were positive for at least one test, whereas in the control, anti-HBc was positive in 30.1% and 34.1% were positive for at least one test, the differences between the two groups being significant (P less than 0.01). The frequencies of positive tests for HBsAg and anti-HBc were the highest in HCC followed in decreasing order by cirrhosis, chronic hepatitis and the control group. A possible role of HB virus infection in hepatocellular carcinoma is discussed in relation to other factors.
对124例肝细胞癌（HCC）患者检测了乙肝表面抗原（HBsAg）、抗-HBs和抗-HB核心抗体（HBc），并与299名年龄相仿的对照者进行比较，同时检测了48例慢性肝炎患者和52例肝硬化患者。结果发现，72.6%的HCC患者抗-HBc呈阳性，80.6%的患者至少一项检测呈阳性；而在对照组中，抗-HBc阳性率为30.1%，至少一项检测呈阳性的比例为34.1%，两组之间差异有统计学意义（P<0.01）。HBsAg和抗-HBc检测阳性率在HCC患者中最高，其次按降序排列为肝硬化、慢性肝炎和对照组。结合其他因素讨论了乙肝病毒感染在肝细胞癌中的可能作用。
